# Clinical Trials Data KIT - Document 23

# Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding

## Clinical Trial: https://clinicaltrials.gov/study/NCT01282853

"eligibilityCriteria": "Inclusion Criteria:\n\n\* gastroduodenal ulcer with bleeding, documented by endoscopic examination\n\nExclusion Criteria:\n\n\* 1. receiving continuous proton pump inhibitor treatment, antibiotics within 4 weeks 2. not suitable for endoscopic biopsy 3. hemodynamically unstable",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
To determine if a patient with a KIT gene mutation is eligible for the clinical trial, we would need to know if the trial specifically excludes patients with genetic mutations like KIT mutations. Based on the eligibility criteria provided, there is no mention of genetic mutations, including KIT, either as an inclusion or exclusion criterion.  
  
The main criteria for the trial focus on:  
  
1. Inclusion Criteria:  
 - The patient must have a gastroduodenal ulcer with bleeding, confirmed by endoscopic examination.  
  
2. Exclusion Criteria:  
 - The patient should not be receiving continuous proton pump inhibitor treatment or antibiotics within 4 weeks.  
 - The patient should be suitable for endoscopic biopsy.  
 - The patient must be hemodynamically stable.  
  
Since KIT gene mutation is not mentioned, it would not directly impact eligibility based on the provided criteria. Therefore, a patient with a KIT gene mutation would likely be eligible for the trial as long as they meet the inclusion criteria and do not meet any of the exclusion criteria. However, it is always best to consult with the trial coordinators for confirmation, as there may be additional criteria or considerations not disclosed in this excerpt.